HDL Cholesterol (High-Density Lipoprotein) Test
The HDL cholesterol test measures the cholesterol carried within high-density lipoprotein particles, a core component of the lipid profile and cardiovascular risk assessment. Low HDL-C is an independent risk marker, but HDL-C reflects cholesterol concentration rather than HDL function and is a risk marker, not a validated treatment target;
1
Biomarkers
Blood (serum)
Sample
1–3 business days
Turnaround
No — HDL-C is minimally affected by fasting; a fasting sample is preferable only if a full lipid panel with calculated LDL-C is being performed
Fasting
What is the HDL-C test?
The HDL Cholesterol Test measures the cholesterol carried within high-density lipoprotein particles. HDL is central to reverse cholesterol transport, and HDL-C is a routine component of the lipid profile, an input to cardiovascular risk scoring, and a value required to derive non-HDL cholesterol and calculated LDL-C. Low HDL-C is a well-established independent risk marker, most often ordered as part of a standard lipid panel during cardiovascular risk assessment. Within lipid assessment, HDL-C is straightforward to measure but nuanced to interpret. Although low HDL-C reliably flags elevated risk, HDL-C reflects a cholesterol concentration rather than HDL particle number or function, and it is a risk marker rather than a validated therapeutic target — pharmacological HDL-raising has not improved outcomes, and the association with risk is not linear. Several large cohorts describe a U-shaped relationship in which very high HDL-C carries increased rather than reduced mortality, so an unusually high value is not straightforwardly reassuring. HDL-C is therefore read alongside LDL-C, non-HDL-C, triglycerides, and the patient's overall risk; apolipoprotein A-I and HDL particle measures exist but add little to routine assessment.
What does the HDL-C test measure?
High-density lipoprotein is the smallest, densest lipoprotein, assembled in the liver and intestine around apolipoprotein A-I. It is central to reverse cholesterol transport, accepting cholesterol from peripheral tissues — including macrophages within the arterial wall — and returning it to the liver for excretion, and it carries anti-inflammatory and antioxidant activity. HDL-C is the cholesterol contained within these particles; it is a measure of cholesterol concentration, not of HDL particle number or particle function.
HDL-C is a core component of the lipid profile and an input to cardiovascular risk scoring, and is required to derive non-HDL cholesterol and calculated LDL-C. Low HDL-C is an independent, epidemiologically robust risk marker, but it is a marker rather than a validated treatment target: raising HDL-C pharmacologically (CETP inhibitors, niacin) has not reduced cardiovascular events, and Mendelian randomisation does not support a simple causal protective effect. It is therefore interpreted within the full lipid profile and global risk rather than in isolation.
Why is the HDL-C test ordered?
- Routine cardiovascular risk assessment as part of a standard lipid profile
- Cardiovascular risk stratification where HDL-C is a required input to a risk equation (for example ASCVD or QRISK scoring)
- Derivation of non-HDL cholesterol and calculated LDL-C, both of which require a measured HDL-C
- Investigation of dyslipidaemia and metabolic syndrome, where low HDL-C is common in insulin resistance, type 2 diabetes, and central obesity, and is itself a defining criterion
- Monitoring the lipid response to lifestyle intervention — smoking cessation, weight loss, increased physical activity — where HDL-C may change over time
- Evaluation of markedly low HDL-C suggesting a familial disorder (Tangier disease, apolipoprotein A-I or LCAT deficiency) or a secondary cause such as androgen use
- Contextualisation of an unexpectedly high HDL-C, where the U-shaped association with risk warrants interpretation rather than automatic reassurance
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No — HDL-C is minimally affected by fasting; a fasting sample is preferable only if a full lipid panel with calculated LDL-C is being performed
Collection method
Venipuncture at patient service centre
Turnaround
1–3 business days
Collection notes
Defer testing during acute illness or shortly after myocardial infarction. Document androgen or anabolic steroid use, oestrogens, fibrates, niacin, alcohol intake, and pregnancy status. Where triglycerides are markedly elevated, interpret with the assay's limitations in mind. Use the same assay for serial monitoring.
Specimen requirements
Minimum 0.5 mL serum. Separate serum from cells per Access Medical Laboratories protocol. Specimen stable refrigerated; follow Access Medical Laboratories transport guidelines.
What can affect HDL-C results?
Very high triglycerides can interfere with some homogeneous HDL-C assays and reduce measurement reliability, so results at markedly elevated triglycerides should be interpreted with the performing laboratory's method in mind.
The acute-phase response transiently lowers HDL-C, and levels fall for days to weeks after a myocardial infarction, so measurement should be deferred or interpreted with caution during acute illness.
Cigarette smoking lowers HDL-C, and smoking cessation is associated with a rise, independent of other lipid changes.
Regular alcohol consumption raises HDL-C; this is a laboratory observation rather than a therapeutic rationale, and intake should be documented when interpreting an elevated value.
Anabolic steroids and androgens can lower HDL-C markedly, oestrogens tend to raise it, and fibrates and niacin raise it while some non-selective beta-blockers lower it. Medication history should be documented.
HDL-C rises physiologically during pregnancy, so gestational results are not interpreted against standard thresholds.
What do HDL-C results mean?
Elevated
HDL-C of 60 mg/dL or above has traditionally been regarded as favourable and a negative risk factor. However, very high HDL-C — roughly above 90–100 mg/dL — is associated with increased mortality in several cohorts, so extreme elevation is not straightforwardly protective and may reflect alcohol, oestrogen exposure, or genetic variants such as CETP deficiency. High values are interpreted in context rather than taken as reassurance.
Normal
An HDL-C within the desirable range is interpreted against the patient's overall cardiovascular risk and the rest of the lipid profile. A desirable HDL-C does not offset an elevated LDL-C or non-HDL-C, and does not by itself establish low risk.
Reduced
Low HDL-C (below 40 mg/dL in men, below 50 mg/dL in women) is an independent cardiovascular risk marker and is common in metabolic syndrome, insulin resistance, type 2 diabetes, obesity, smoking, and physical inactivity, and alongside hypertriglyceridaemia. Markedly low HDL-C (roughly below 20–25 mg/dL) raises suspicion of a familial disorder or a secondary cause such as androgen use or severe illness.
Note: HDL-C measures cholesterol concentration within HDL, not HDL particle number or function, and it is a risk marker rather than a validated treatment target — pharmacological HDL-raising has not reduced cardiovascular events. The association with risk is U-shaped, so both low and very high values carry meaning. Assay performance can degrade at markedly elevated triglycerides, and serial monitoring should use the same method.
Frequently asked questions
It measures the cholesterol carried within high-density lipoprotein particles, a routine component of the lipid profile. HDL-C reflects cholesterol concentration rather than HDL particle number or function.
How to access the HDL-C test
The HDL-C reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: July 16, 2026
Last reviewed: July 16, 2026
- Grundy SM, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol. Circulation. (2019)
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. (2020)
- Voight BF, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. (2012)
- Madsen CM, et al. Extreme high HDL cholesterol is paradoxically associated with high mortality in men and women. Eur Heart J. (2017)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Lipid Panel
The standard lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, and derives non-HDL cholesterol, providing the core assessment of cardiovascular lipid risk. LDL-C is the principal treatment target and non-HDL-C an increasingly used secondary measure.
cardiovascular
Direct LDL-C
The direct LDL cholesterol test measures LDL-C analytically rather than deriving it from the Friedewald calculation used in standard lipid panels. It is preferred where the calculation fails — when triglycerides exceed roughly 400 mg/dL, at very low LDL-C, and in non-fasting samples.
cardiovascular
Total Cholesterol
The total cholesterol test measures the sum of cholesterol carried across all lipoprotein fractions, including LDL, VLDL, and HDL. Because it aggregates atherogenic and protective fractions, an elevated total cannot be interpreted for cardiovascular risk without the individual fractions, and treatment targets are set on LDL cholesterol and non-HDL cholesterol rather than total cholesterol.